Revolution Medicines, Inc. Revolution Medicines, Inc.

Revolution Medicines, Inc.

RVMD

株式のランク #580
Revolution Medicines, Inc. is a precision oncology firm operating in the... Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
株価
$196.16
最終同期: 2026-10-20
時価総額
$42.04B
変化（1日）
7.69%
変化（1年）
266.72%
国
US
取引 Revolution Medicines, Inc. (RVMD)

カテゴリー

Healthcare
Revolution Medicines, Inc.（RVMD）の発行済株式数
June 2026 時点の発行済株式数 210.89M
Revolution Medicines, Inc. の最新の財務報告および株価によると、現在の発行済株式数は 210.89M です。December 2023 の終わりには、同社は 113.15M 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
Revolution Medicines, Inc.（RVMD）の発行済株式数の履歴（2017 ～ 2026）
各年末時点の発行済株式数
年 発行済株式数 変化
2026 (TTM) 210.89M 25.73%
2024 167.74M 48.24%
2023 113.15M 40.34%
2022 80.63M 10.74%
2021 72.81M 9.32%
2020 66.60M 82.60%
2019 36.47M 0.00%
2018 36.47M 0.00%
2017 36.47M 0.00%
類似企業や競合他社の発行済株式数
企業 発行済株式数 差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M 20.39%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M 87.77%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 478.91M 127.09%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -70.51%
NL